Lenalidomide Mylan 15 mg hard capsules
Authorisation EU/1/20/1490/011-012 · Mylan Pharmaceuticals Limited
- Licence holder
- Mylan Pharmaceuticals Limited (all products →)
- Active substance
- Lenalidomide
- Clinical trials
- 177 clinical trials →
- Dosage form
- Capsule, hard
- Route of administration
- Oral use
- ATC code
- L04AX04
- First authorised
- 18/12/2020
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Generic application (Article 10(1) of Directive No 2001/83/EC)
Lenalidomide: supply and approvals
55 authorised products on the HPRA list contain Lenalidomide. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 18 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 18 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 18 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 1490. It has been authorised for 5 years (since 18 December 2020). The HPRA list does not say whether it is on sale.
Other medicines with Lenalidomide in Ireland
54 other products on the HPRA list contain Lenalidomide, from 9 licence holders; 14 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Lenalidomide Clonmel 10 mg hard capsules | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Lenalidomide Clonmel 15 mg hard capsules | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Lenalidomide Clonmel 20 mg hard capsules | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Lenalidomide Clonmel 25 mg hard capsules | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Lenalidomide Clonmel 5 mg hard capsules | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Lenalidomide Rowex 10 mg hard capsules | Rowex Limited, | National authorisation (PA) | Marketed |
| Lenalidomide Rowex 15 mg hard capsules | Rowex Limited, | National authorisation (PA) | Marketed |
| Lenalidomide Rowex 25 mg hard capsules | Rowex Limited, | National authorisation (PA) | Marketed |
| Lenalidomide Rowex 5 mg hard capsules | Rowex Limited, | National authorisation (PA) | Marketed |
| Lenalidomide Teva 10 mg hard capsules | Teva B.V. | National authorisation (PA) | Marketed |
| Lenalidomide Teva 15 mg hard capsules | Teva B.V. | National authorisation (PA) | Marketed |
| Lenalidomide Teva 20 mg hard capsules | Teva B.V. | National authorisation (PA) | Marketed |
The licence holder
Mylan Pharmaceuticals Limited holds 45 products on the HPRA list, with 26 different active substances; 0 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 19 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.